2025.07.01本文字数:1534,阅读时长大约3.9分钟导读:金斯瑞生物科技控股子公司蓬勃生物与礼新医药合作的抗PD - 1单域抗体全球许可项目,累计回款已达2.138亿美元。这一合作不仅为金斯瑞带来可观收益,更展现了国内Biotech企业“技术共享 + 分成”模式的创新与突破,为行业出海提供新思路。在国内创新药“出海”大潮中,CXO企业已然成为至关重要的一环。6月30日,金斯瑞生物科技发布...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.